Comparative Pharmacology
Head-to-head clinical analysis: INCIVEK versus XERESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INCIVEK versus XERESE.
INCIVEK vs XERESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibitor of the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein, thereby inhibiting viral replication.
XERESE is a fixed-dose combination of clobetasol propionate (a corticosteroid) and acitretin (a retinoid). Clobetasol propionate binds to glucocorticoid receptors, modulating gene expression to inhibit pro-inflammatory cytokines and reduce inflammation. Acitretin binds to retinoic acid receptors (RARs) and retinoid X receptors (RXRs), regulating keratinocyte proliferation and differentiation.
Incivek (telaprevir) is administered orally at a dose of 750 mg (two 375 mg tablets) three times daily (every 7-9 hours) with food (not low-fat).
One vaginal tablet (100 mg clindamycin + 200 mg clotrimazole) intravaginally once daily at bedtime for 3 consecutive days.
None Documented
None Documented
Terminal elimination half-life ranges from 4 to 13 hours (mean ~7 hours) in healthy volunteers; prolonged to 10-20 hours in HCV-infected patients.
Terminal half-life is approximately 8.5 hours (6–11 h) in healthy adults, supporting twice-daily dosing.
Approximately 91% of the radiolabeled dose is recovered in feces (79% as unchanged drug) and 9% in urine (1% as unchanged drug).
Renal: ~51% as unchanged drug; fecal: ~33% (partially as metabolites).
Category C
Category C
Antiviral
Antiviral